216 related articles for article (PubMed ID: 18623899)
21. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.
Thyagu S; Minden MD; Gupta V; Yee KW; Schimmer AD; Schuh AC; Lipton JH; Messner HA; Xu W; Brandwein JM
Br J Haematol; 2012 Aug; 158(4):506-14. PubMed ID: 22650180
[TBL] [Abstract][Full Text] [Related]
22. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
23. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.
Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E
Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824
[TBL] [Abstract][Full Text] [Related]
24. The development and application of imatinib.
Jones RL; Judson IR
Expert Opin Drug Saf; 2005 Mar; 4(2):183-91. PubMed ID: 15794712
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib: for some difficult cases of adult leukaemia.
Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
[No Abstract] [Full Text] [Related]
26. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
27. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
28. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
29. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Zembutsu H; Yanada M; Hishida A; Katagiri T; Tsuruo T; Sugiura I; Takeuchi J; Usui N; Naoe T; Nakamura Y; Ohno R
Int J Oncol; 2007 Aug; 31(2):313-22. PubMed ID: 17611687
[TBL] [Abstract][Full Text] [Related]
30. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
32. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
Sørensen AL; Larsen H
Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
[TBL] [Abstract][Full Text] [Related]
34. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival.
Burke MJ; Trotz B; Luo X; Baker KS; Weisdorf DJ; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Jan; 43(2):107-13. PubMed ID: 18776928
[TBL] [Abstract][Full Text] [Related]
35. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
36. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Chang H; Shih LY
Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
[TBL] [Abstract][Full Text] [Related]
37. Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
Judson I
Curr Opin Oncol; 2008 Jul; 20(4):433-7. PubMed ID: 18525340
[TBL] [Abstract][Full Text] [Related]
38. Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Cross SA; Lyseng-Williamson KA
Drugs; 2007; 67(17):2645-54. PubMed ID: 18034597
[TBL] [Abstract][Full Text] [Related]
39. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
[TBL] [Abstract][Full Text] [Related]
40. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Breccia M; Alimena G
Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
